Fund Performance
Lumpsum
SIP
23.55
as on 19 May 20223 Years
Investment of ₹ 10,000 in this fund 3 Years back would be ₹ 18,890 today.
NAV Performance
Fund Information
-
₹ 266.097
as on 19 May 2022 -
Regular - Growth
-
-
-
₹ 5,000
-
₹ 5,224 Cr.
as on 31 Dec 2021 -
2%
-
02 Jan 2013
-
S&P BSE Healthcare TRI
-
Nippon India Mutual Fund
Show All Funds -
Nippon India Pharma Fund - Growth charges 1.0% of sell value; if fund sold before 30 days. There are no other charges.
Highlights of this fund
Nippon India Pharma Fund is an Open-ended Equity Fund. The fund belongs to Sectoral/Thematic category, where the investment is done in predominantly in stocks that are listed on Stock Exchanges like the Bombay Stock Exchange (BSE) or the National Stock Exchange (NSE) in India as well as Global stock exchanges like the Dow Jones, London Stock Exchange or LSE etc. This fund was started on 02 Jan 2013. This fund is offered by one of the top AMC (Assets Management Company) Nippon India Mutual Fund. You can also view here all other Equity funds offered by Nippon India Mutual Fund.
Latest NAV of the fund is ₹ 266.097 as on 19 May 2022.
This fund has 9 years of track record. Since 30 Nov 2021 expense ratio of this fund is 2%. Ideally you shoulds compare this fund with the benchmark S&P BSE Healthcare TRI.
You can invest in this fund in SIP with the minimum investment of ₹ 100. Lumpsum invest is offered with minimum investment of ₹ 5,000.
Fund Objective
To generate consistent returns by investing in equity,equity related of fixed income securities of Pharma and other associated companies.
List of Fund Managers of Nippon India Pharma Fund
-
About Sailesh Raj Bhan
Mr. Sailesh Raj Bhan has over 24 years of experience in Indian Equity Markets with over 15 years at Reliance Nippon Life Asset Management Limited in Fund Management. He manages the flagship diversified equity schemes like Reliance Multi Cap Fund (previously Reliance Equity Opportunities Fund) - a strategy with assets of over Rs10,000cr ($1.5bn) since its inception in March 2005 and Reliance Large Cap Fund (previously Reliance Top200 Fund) – with assets of over Rs13000cr (over $1.8bn) since its inception 2007. Sailesh also manages the Largest Pharma Sector Fund in India since its inception 15 years back in May 2004, in addition to managing Reliance Consumption Fund – a broad based Consumption Thematic product since 2004. He also advises on international mandates for some strategies for the last 5 years.
Riskometer : Risk associated with this fund
Investors understand that their principal will be at High Risk
Fund Return Comparison
| Fund Name | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | 5 Years | 10 Years | 1 Year | 2 Years | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Category Best | 0.04% | 11.29% | 17.99% | 24.34% | 78.08% | 32.55% | 26.81% | 22.01% | 34.55% | 48.85% | 44.27% | 28.80% | 21.94% |
| Category Average | -7.84% | -6.76% | -10.68% | 5.61% | 36.06% | 15.18% | 10.10% | 13.94% | -9.44% | 15.71% | 17.67% | 12.95% | 12.69% |
| Nippon India Pharma Fund | -8.38%₹ 9,161 | -5.39%₹ 9,461 | -11.82%₹ 8,818 | -8.53%₹ 9,147 | -18.43%₹ 10,776 | 22.85%₹ 15,091 | 4.29%₹ 25,076 | 23.55%₹ 18,890 | 17.80%₹ 46,786 | 15.77%₹ 20,807 | 17.17%₹ 92,092 | 16.76%₹ 47,155 | 14.59%₹ 2,57,351 |
| Quant Infrastructure Fund | -11.11%₹ 8,889 | -6.11%₹ 9,389 | -6.69%₹ 9,330 | 21.23%₹ 12,123 | 5.22%₹ 12,334 | 76.51%₹ 31,156 | 48.85%₹ 37,223 | 32.55%₹ 23,341 | 44.27%₹ 66,510 | 19.83%₹ 24,721 | 28.80%₹ 1,21,859 | 14.85%₹ 39,981 | 19.31%₹ 3,31,771 |
| ICICI Prudential Technology Fund | -9.84%₹ 9,015 | -14.90%₹ 8,509 | -21.01%₹ 7,899 | 15.77%₹ 11,576 | -20.74%₹ 10,617 | 62.78%₹ 26,496 | 25.31%₹ 30,587 | 30.80%₹ 22,429 | 34.52%₹ 58,705 | 26.57%₹ 32,503 | 28.61%₹ 1,21,323 | 22.01%₹ 73,215 | 21.94%₹ 3,82,411 |
| Quant Consumption Fund | -10.63%₹ 8,937 | -6.34%₹ 9,366 | -10.26%₹ 8,974 | 12.35%₹ 11,235 | -6.57%₹ 11,573 | 56.28%₹ 24,422 | 31.48%₹ 32,280 | 29.58%₹ 21,804 | 35.43%₹ 59,411 | 16.38%₹ 21,357 | 23.86%₹ 1,08,305 | 17.79%₹ 51,499 | 19.74%₹ 3,39,483 |
| Aditya Birla Sun Life Digital India Fund | -10.93%₹ 8,906 | -15.08%₹ 8,491 | -19.46%₹ 8,054 | 11.19%₹ 11,118 | -21.99%₹ 10,530 | 51.46%₹ 22,939 | 19.88%₹ 29,126 | 29.08%₹ 21,552 | 29.35%₹ 54,825 | 25.84%₹ 31,578 | 26.10%₹ 1,14,280 | 20.61%₹ 65,225 | 20.94%₹ 3,62,318 |
| Tata Digital India Fund | -11.48%₹ 8,851 | -15.36%₹ 8,464 | -20.84%₹ 7,916 | 14.21%₹ 11,420 | -21.39%₹ 10,572 | 53.45%₹ 23,547 | 21.71%₹ 29,615 | 26.77%₹ 20,414 | 29.59%₹ 55,000 | 26.81%₹ 32,813 | 26.39%₹ 1,15,089 | - | - |
Portfolio Holdings
Top Sector Holdings of Nippon India Pharma Fund
| Name of Sector | Holding Percentage | Holding Values in Crore |
|---|---|---|
| Pharmaceuticals | 76.57% | ₹ 4,131.98 Cr. |
| Hospital | 16.57% | ₹ 894.34 Cr. |
| Healthcare service providers | 5.47% | ₹ 295.34 Cr. |
| Medical equipment & supplies | 0.51% | ₹ 27.79 Cr. |
| Others | .88% | - |
Top Stock Holdings of Nippon India Pharma Fund
| Name of Stocks | Holding Percentage | Holding Values in Crore |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 11.91% | ₹ 642.82 Cr. |
| Dr. Reddys Laboratories Ltd. | 9.55% | ₹ 515.24 Cr. |
| Cipla Ltd. | 8.75% | ₹ 472.05 Cr. |
| Aurobindo Pharma Ltd. | 7.62% | ₹ 411.24 Cr. |
| Lupin Ltd. | 7.40% | ₹ 399.32 Cr. |
| Others | 54.77% | - |
Other Holdings
| Holding Type | Holding Percentage |
|---|---|
| TREPS | 1.17% |
| Margin | 0.17% |
| Net Receivables | -0.46% |